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1, 25 Dihydroxyvitamin D, (1,25-(OH),D,) and a number of synthetic vitamin D, analogues with low 
calcaemic activity, have been shown to inhibit breast cancer cell growth in vitro as well as in viva. The 
purpose of the present study was to investigate a possible interaction of 1,25-(OH),D, and the vitamin 
D3 analogue EB1089 with the insulin-IGF-I regulatory system. The oestrogen receptor-positive MCF- 
7 human breast cancer cells used in this study are able to grow autonomously and their growth is 
stimulated by insulin. In order to avoid interference of IGF-binding proteins (IGF-BPS), we used an 
analogue of IGF-I, long R3 IGF-I, which stimulated MCF-7 cell growth similar to insulin. The growth 
stimulation by insulin and by long R3 IGF-I was completely inhibited by 1,25-(OH),D, and EB1089. 
Autonomous growth was also inhibited by 1,25-(OH),D, and EB1089. The analogue EB1089 was active 
at 50 times lower concentrations than 1,25-(OH),D3. It was shown that growth inhibition was not 
achieved through downregulation of insulin and IGF-I binding after 48 h. Paradoxically, after pro- 
longed treatment (8 days), an upregulation of insulin and IGF-I binding was observed. Two possible 
intracellular mediators of the insulin-IGF mitogenic signal are C-FOS and mitogen-activated protein 
(MAP) kinase. Insulin-induced C-FOS mRNA was inhibited by 1,25-(OH),D3, suggesting that it could 
be involved in the growth inhibition by 1,25-(OH),D,. MAP kinase activation appeared not to be 
involved in growth stimulation by both insulin and IGF-I. Together, the present study demonstrates 
that vitamin D, compounds can block the mitogenic activity of insulin and IGF-I, which may contribute 
to their tumour suppressive activity observed in z&o. Copyright 0 1996 Elsevier Science Ltd 
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INTRODUCTION 
BESIDES REGULATION of calcium and bone metabolism, the 
most active metabolite of vitamin D, 1,25dihydroxyvitamin 
D, (1, 25(OH),D,), regulates growth and differentiation of a 
wide variety of cells and tissues [ 1, 21. Both in vitro and in vivo 
studies have shown that 1,25-(OH),D, inhibits the growth of 
breast cancer cells [3-71 and these findings suggest a potential 
use of 1,25-(OH),D, for the treatment of breast cancer. A 
major drawback is that high doses are needed for tumour 
suppression. This may result in undesirable side-effects, such 
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as the development of hypercalcaemia. To overcome these 
problems, a number of promising synthetic vitamin D, ana- 
logues have been developed, with more potent effects on 
growth and differentiation and a reduced in vivo calcaemic 
activity [8, 93. 
Breast cancer growth is regulated by numerous factors, 
including steroid hormones and polypeptide growth factors 
[lo]. Insulin, insulin-like growth factor-I (IGF-I) and insulin- 
like growth factor-II (IGF-II) are structurally related mol- 
ecules which are believed to play an important role in promot- 
ing breast tumour growth [l l-141. The IGFs and insulin are 
derived from the circulation. The IGFs are also produced by 
breast tumour cells and by neighbouring stromal cells in the 
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breast tumour, and can act in an autocrine or paracrine 
manner [ 11, 13, 151. These three polypeptide hormones exert 
their biological activity by binding to distinct transmembrane 
receptors: the closely related insulin and type I IGF receptor, 
and the type II IGF receptor or mannose-6-phosphate recep- 
tor. Considerable crossreactivity exists between the various 
ligands and receptors [ 161. In addition to the three receptors, 
the IGFs bind to other binding proteins which are found in 
serum and are produced by a wide variety of different cell 
types. To date, six IGF binding proteins (IGF-BPS) have been 
cloned [17]. Breast tumours and breast cancer cell lines 
express IGF-BP2 to IGF-BP6 in a heterogenous pattern, 
while little or no expression of IGF-BP1 is seen [18-201. At 
the cellular level, IGF-BPS can either potentiate or suppress 
the activity of the IGFs [ 17, 181. 
In earlier reports, we studied the interference of 1,25- 
(OH),D, with the growth stimulation of human breast cancer 
cell lines by oestradiol. It was shown, in MCF-7 cells, that 
inhibition by 1,25-(OH),D, and several vitamin D3 analogues 
was independent of oestradiol [7, 211. So far, no data are 
available on the interaction of vitamin D, compounds with the 
insulin and IGF-I regulatory system of breast cancer cells. In 
the present study, we investigated the effects of 1,25-(OH),D, 
and a promising vitamin D, analogue, EB1089, on insulin- 
and IGF-I-stimulated growth of MCF-7 cells. As IGF-BPS 
are important, but often complex, regulators of IGF actions, 
we avoided an interference with IGF-PBS produced by MCF- 
7 cells by using insulin and analogues of IGF-I, long R3 IGF- 
I and des(l-3)IGF-I, which have a reduced binding to IGF- 
BPS. Furthermore, we studied the effects of 1,25-(OH),D, 
and EB1089 on insulin and IGF-I binding, and intracellular 
mediators of the insulin-IGF signal: C-FOS mRNA 
expression [22, 231 and mitogen-activated protein (MAP) 
kinase activity [24]. 
MATERIALS AND METHODS 
Chemicals 
1,25-(OH),D, and EB1089 [25] were kindly donated by 
Dr L. Binderup of LEO Pharmaceutical Products (Ballerup, 
Denmark). The chemical structure of EB1089 is depicted in 
Figure 1. Insulin, RPMI-1640 cell culture medium, human 
transferrin, sodium selenite and bacitracin were purchased 
from Sigma Chemical Co. (St Louis, Missouri, U.S.A.). IGF- 
I, long R3 IGF-I and des(llS)IGF-I were obtained from 
GroPep Pty Ltd (Adelaide, Australia). Long R3 IGF-I is an 
analogue of human IGF-I synthesised in E. coli and has a 
substitution of an Arg for Glu at position 3 and an extension 
of 13 amino acids at the N-terminus [26]. Des(l-3) is a 
HO 
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Figure 1. Chemical structures of 1,25-(OH),D, and EB1089. 
truncated form of IGF-I which lacks three N-terminal 
amino acids [27]. [1125]insulin labelled at tyrosine-A14 
(2000 Ciimmol) and [1251]IGF-I (2000 Wmmol) were Tom 
Amersham International (Buckinghamshire, U.K.). The aIR3 
antibody against the type I IGF receptor was purchased from 
Oncogene Science Inc. (Uniondale, New York, U.S.A.). Bov- 
ine serum albumin fraction V (BSA) was purchased from ICN 
Biomedicals Inc. (Costa Mesa, California, U.S.A.). Gluta- 
mine, penicillin and streptomycin were obtained from Life 
Technologies (Paisley, U.K.), and fetal calf serum (FCS) was 
obtained from Sera-Tech Zellbiologische Produkte GmbH 
(St Salvator, Germany). 
Cell culture 
MCF-7 cells were generously provided by Dr J.A. Foekens, 
Dr Daniel den Hoed Cancer Centre (Rotterdam, The 
Netherlands). MCF-7 cells were routinely maintained in phe- 
nol red-free RPMI-1640 medium supplemented with 2 mM 
glutamine, 100 U/ml penicillin, 100 p&ml streptomycin, 
24 mM sodium bicarbonate (basal RPM1 medium) plus 10% 
FCS and 10 p&ml insulin. Prior to the start of the exper- 
iments, the cells were deprived of insulin and serum as follows: 
the cells were trypsinised and seeded in phenol red-free basal 
RPM1 medium supplemented with 2% charcoal-treated FCS 
(25 000 cells/cm’). The FCS was added for the attachment of 
the cells. After 24 h, the medium was changed to serum- 
free basal RPM1 medium supplemented with 2 mg/ml BSA, 
10 pgiml transferrin and 30 nM sodium selenite (SFM). The 
medium was replaced every 2-3 days. After 1 week, the cells 
had grown to subconfluence and the procedure was repeated. 
For the experiments, cells that were cultured in SFM for 
several weeks were used. The experiments were started by 
seeding the cells in basal RPM1 medium supplemented with 
2% charcoal-treated FCS. After 24 h, the medium was 
changed to SFM and, after another 24 h, the SFM was 
refreshed and the agents to be tested were added. For long- 
term experiments, the medium and test agents were replaced 
every 3 days. 
Proliferation experiments 
MCF-7 cells were seeded into 24-well dishes at a density of 
4000 cells/cm* and incubated with the compounds to be 
tested as described above. After 8 days of incubation, DNA 
content was measured using the ethidium bromide method as 
described previously [7]. 
Insulin and ZGF-Z binding 
The insulin and IGF-I binding assay was performed as 
described by Maassen and associates [28]. For short-term 
incubations, MCF-7 cells were grown to subconfluence in 
SFM in six-well dishes and were subsequently exposed to 
the vitamin D, compounds for 24 or 48 h. For long-term 
incubations (8 days), the cells were exposed to the vitamin D3 
compounds from the start of the experiment as described 
above. At the end of both the short- and long-term incu- 
bations, the cells were washed twice in PBS (pH 7.8) plus 
10 mg/ml BSA. Subsequently, the cells were incubated with 
3 X lO_” M [‘251]insulin in PBS (pH 7.8) plus 10 mgiml 
BSA for 2.5 h at room temperature or with 3 X lo-” M 
[‘251]IGF-I in PBS (pH 7.8) plus 10 mg/ml BSA and 2 mgiml 
bacitracin for 3.5 h at 4°C. Non-specific binding was assessed 
by incubating the cells with labelled insulin in the presence of 
1 PM unlabelled insulin or with labelled IGF-I in the presence 
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of 0.1 uM unlabelled IGF-I. After the incubation, the cells 
were washed 5 times with ice-cold PBS plus 1 mg/ml BSA and 
solubilised in 0.1 M NaOH, 0.1% SDS. The amount of 
bound [‘251]insulin or [“51]IGF-I was determined in a gamma 
counter (NE1 600, NE Technology Ltd, Reading, U.K.) and 
corrected for the absorption at 260 nm, which was used as a 
measure for the cell number. 
Assay of MAP kinase activity 
MCF-7 cells were seeded (2 X 1 O4 cells/cm*) and incubated 
with the compounds to be tested for 5-30 min as described 
above. Upon activation, MAP kinase is phosphorylated. Acti- 
vation of MAP kinase was detected by immunoblotting of cell 
homogenates as described by Van den Berghe and associates 
[29]. The method is based on a shift in gel electrophoretic 
migration owing to phosphorylation of MAP kinase. 
RNA isolation and hybridisation 
Cells were seeded (1.5 X lo6 cells/25 cm’ flask), and incu- 
bated with the compounds to be tested as described above. 
Total RNA was isolated by guanidinium thiocyanate-phenol- 
chloroform extraction and Northern analysis with lo-20 kg 
RNA was performed as described previously [2 11. Northern 
blots were hybridised with 32P-labelled human cDNA frag- 
ments specific for C-FOS [30] and GAPDH [31]. After 
hybridisation, the Northern blots were washed twice in 
2 X SSC, 0.1% SDS for 5 min at room temperature, twice in 
2 X SSC, 0.1% SDS for 20 min at 60°C and twice in 
0.5 X SSC, 0.1% SDS for 20 min at 6O’C. Membranes were 
exposed to medical X-ray films (Fuji Photo Film Co., Tokyo, 
Japan) with intensifying screens at -8O”C, and the autoradio- 
graphs were quantified using a ScanJet IIcx scanner (Hewlett- 
Packard Co., Minneapolis, U.S.A.). Before rehybridisation 
with GAPDH, Northern blots were washed in 5 mM Triss 
HCl (pH 8.0), 0.2 mM EDTA (pH 8.0), 0.05% sodium pyro- 
phosphate and 0.1 X Denhardt’s solution for at least 2 h 
at 65°C. 
RESULTS 
Inhibition of insulin- and IGF-I-stimulated growth by vitamin D, 
compounds 
The MCF-7 cells in our laboratory are able to grow auto- 
nomously in SFM without further additions. The autonomous 
growth was stimulated by treatment with insulin. After 8 days 
of treatment, the DNA content of the wells containing SFM 
supplemented with insulin was 1.5-2-fold higher than the 
DNA content of the control wells without insulin. The insulin 
dose-response curve was steep, with maximum growth stimu- 
lation reached at 5 kg/ml and a median effective concentration 
of 1 kg/ml insulin (Figure 2). 
The growth stimulation by 10 ng/ml insulin could be dose- 
dependently inhibited both by 1,25-(OH),D, and the vitamin 
D, analogue EB1089 (Figure 3). Based on the median effec- 
tive concentration, EB 1089 was approximately 50 times more 
potent than 1,25-(OH)*D3 in the inhibition of insulin-stimu- 
lated growth. Both vitamin D, compounds not only reversed 
the growth stimulation by insulin, but also inhibited part of 
the autonomous growth of MCF-7 cells. 
Since insulin binds not only the insulin receptor but also 
the IGF type I receptor with low affinity [ 161, it is possible 
that the observed stimulation by supraphysiological concen- 
trations of insulin is mediated via the type I IGF receptor. To 
test this possibility, we studied whether the insulin-stimulated 
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Figure 2. Growth stimulation of MCF-7 cells by insulin and 
long R’ IGF-I. Cells were cultured for 8 days in SFM, as 
described in Materials and Methods, with various concen- 
trations of insulin or long R3 IGF-I. Subsequently, DNA con- 
tent was measured. Each point represents mean k SD. of 
duplicate wells. 
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Figure 3. Inhibition of insulin-stimulated growth of MCF-7 
cells by 1,25-(OH),D, and EBlOS9. Cells were cultured for 
8 days in SFM supplemented with 10 pg/ml insulin and the 
indicated concentrations of the vitamin D, compounds or 
vehicle (0.1% ethanol) as described in Materials and Methods. 
Each point represents mean 2 S.D. of duplicate wells. 
growth could be inhibited by the type I IGF receptor blocking 
antibody aIR3. The antibody inhibited the insulin-stimulated 
growth by 24% and IGF-I-stimulated growth by about 30%. A 
small inhibition of the autonomous growth (9%) was observed 
(data not shown). 
Next, we examined the mitogenic effect of IGF-I on MCF- 
7 cells. To avoid interference with IGF-BPS secreted by MCF- 
7 cells, we tested two analogues of IGF-I, long R3 IGF-I and 
des( l-3)IGF-I, which have reduced binding to IGF-BPS [26, 
271. Figure 2 demonstrates that MCF-7 cells respond to long 
R3 IGF-I with a similar increase of DNA content as obtained 
with insulin. The median effective concentration was 
0.5 pg/ml long R3 IGF-I. Also, for des(l-3)IGF-I relatively 
high concentrations were needed to elicit a proliferative 
response. Des(l-3)IGF-I was not active at concentrations 
below 1 p,g/ml (data not shown). Several studies have shown 
a synergistic action of insulin-IGF-I and oestradiol [32-341. 
However, in our culture system the mitogenic effects of insulin 
and the IGF-I analogues could not be sensitised by co-treat- 
ment with oestradiol (data not shown). 
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Similar to the inhibition of insulin-stimulated growth, the 
growth stimulation by long R3 IGF-I was inhibited by 1,25- 
(OH),D, and the analogue EB1089 (Figure 4). At 10e9 M, 
the differences in potency between 1,25-(OH),D, and 
EB1089 were clearly demonstrated. In addition, Figure 4 
demonstrates that autonomous growth was also potently 
inhibited by 1,25-(OH),D, and EB1089. 
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Insulin and IGF-I binding 
Insulin binding was maximal after 2 h and non-specific 
binding was 9% of the total binding. For IGF-I, the non- 
specific binding was 22% of the total binding. Competitive 
binding studies of [‘251]insulin showed that insulin competed 
at approximately 300 times lower concentrations than IGF- 
I (Figure 5). 
Figure 5. Binding of insulin to monolayers of MCF-7 cells. 
MCF-7 cells were grown to confluence in SFM and incubated 
with 3 x lo-” M [‘Z51]insulin for 2.5 h in the presence of the 
indicated concentrations of unlabelled insulin (solid circles) or 
long IGF-I (triangles). Bound [‘“51]insulin was measured as 
described in Materials and Methods. Data are expressed as 
mean + S.D. of duplicate wells. 
We also studied whether the vitamin D, compounds could 
exert their antiproliferative action on insulin- and IGF-I- 
stimulated growth via regulation of insulin or IGF-I binding. 
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Incubations for 48 h with 1,25-(OH),D, and EB1089 (10m9 
and 10m7 M) had no consistent effect on insulin or IGF-I 
binding (Table 1). In addition, we studied the effect of long- 
term incubations with 1,25-(OH),D, and EB1089 at time- 
points where the growth inhibition by the vitamin D, com- 
pounds was observed. As shown in Table 1, treatment with 
1, 25-(OH),D, and EB1089 resulted in stimulation of insulin 
and IGF-I binding, by approximately 2- and 3-fold, respect- 
ively, of the control. 
Effect of the vitamin D, compounds on intracellular mediators of 
the insulin-IGF-I signal: C-FOS mRNA expression and MAP 
kinase 
10 - 
9 - 
8 - 
7 - 
8 - 
5 - 
4 - 
3 - 
2 - 
1 - 
O- 
- 10-7M EB1089 
AUTONOMOUS LONG R3 IGF-I 
Figure 4. Inhibition of autonomous and long R” IGF-I-stimu- 
lated growth of MCF-7 cells by 1,25-(OH),D, and EB1089. 
Cells were cultured for 8 days in SFM (autonomous growth), 
or SFM supplemented with 1 pg/ml long R3 IGF-I. The cells 
were treated with vehicle (0.1% ethanol), 1,25-(OH),D, (1,25) 
or EB1089 as indicated in the figure. Data are presented as -- __ _. 
mean f S.U. ofduplicate wells. 
Activation of MAI kinase is another intracellular mechan- 
ism involved in the signal transduction of growth factors [24]. 
We examined whether the vitamin D, compounds could affect 
MAP kinase activity as a mechanism for the observed inhi- 
bition of insulin- and long R’ IGF-I-stimulated growth. How- 
ever, in MCF-7 cells, there was no detectable activation of 
MAP kinase by insulin, nor by long R3 IGF-I, in a time course 
from 5 to 30 min. As a positive control of the assay, 10% FCS 
was used, which caused activation of MAP kinase after 10 min 
of incubation (data not shown). 
DISCUSSION 
This study shows that 1,25-(OH),D, and the vitamin D, 
analogue EB1089 are able to reverse the mitogenic effect of 
insulin and an IGF-I analogue (long R3 IGF-I) on MCF-7 
breast cancer cells. The vitamin D, analogue EB1089 was 
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Induction of C-FOS expression is believed to play a central 
role in the transduction of mitogenic signals in the nucleus 
[22, 231. C-FOS mRNA expression was rapidly induced by 
insulin with a peak at 30-60 min and a gradual return towards 
prestimulation level in 4 h (Figure 6). Figure 7 shows that the 
rapid induction of C-FOS mRNA by insulin was inhibited by 
treatment with 1,25-(OH),D,. Basal C-FOS mRNA 
expression was not affected by 1,25-(OH),D, (not shown). 
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Table 1. Insulin and IGF-I binding of MCF-7 cells treated with 1,25-(OH),D, and EB1089 
Short-term incubation (48 h) 
Insulin binding IGF-I binding 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 
Control 1.00 % 0.13 1 .oo 2 0.05 1.00 t- 0.02 1 .oo -t 0.07 
10m9 M 1,25-(OH),D, 1.03 t 0.09 0.99 2 0.01 N.D. N.D. 
lo-’ M 1,25-(OH),D, 1.22 + 0.11 1.25 5 0.33 1.35 2 0.03 1.06 kO.05 
10m9 M EB1089 1.29 ? 0.23 0.98 * 0.02 N.D. N.D. 
1O-7 M EB 1089 1.12 + 0.00 0.85 5 0.10 1.20 + 0.08 1.01 20.08 
Long-term incubation (8 days) 
Insulin binding IGF-I binding 
Exp. 1 Exp. 2 Exp. 1 Exp. 2 
Control 1.00 z 0.20 1.00 t 0.09 1.00 + 0.02 1.00 + 0.04 
10m9 M 1,25-(OH),D, 0.98 -t 0.02 1.25 % 0.26 N.D. N.D. 
1O-7 M 1,25-(OH&D, 1.53 2 0.18 1.65 + 0.11 2.68 2 0.10 3.92 2 0.01 
10m9 M EB1089 1.35 * 0.13 2.39 -c 0.46 N.D. N.D. 
1O-7 M EB1089 1.98 t 0.49 2.30 t 0.45 2.74 -c 0.01 2.63 ? 0.35 
MCF-7 cells were incubated for 48 h or 8 days with or without 1,25-(OH),D, and EB1089 and 
subsequently the specific [‘251]insulin and [‘251]IGF-I binding was measured as described in Materials 
and Methods. Tbe specific binding was corrected for the cell number and expressed as a relative ratio of 
control t S.D. of duplicate wells. 
N.D., not determined. 
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Figure 6. Insulin-induced C-FOS mRNA expression over time. 
MCF-7 cells were incubated with 10 pglml insulin for 0,0.5, 1, 
2 or 4 h. RNA was isolated and Northern blots were prepared 
as described in Materials and Methods and the blots were 
hybridised with “*I’-labelied fos and GAPDH probes. 
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Figure 7. Inhibition of insulin-induced C-FOS mRNA by 1,25- 
(OH),D,. MCF-7 cells were treated without insulin (C) or with 
10 pg/ml insulin and 10-‘“-lO-’ M, 1,25-(OH),D, (lanes 10-7) 
or vehicle (0) for 30 min. The autoradiograph shown was 
quantitated densitometrically. The C-FOS signal was divided 
by the GAPDH signal to correct for equal loading of the lanes. 
Data presented are from a representative experiment which 
was repeated twice with similar results. 
active at 50-fold lower concentrations than the native com- 
pound 1,25-(OH),D,. This is in line with other studies on the 
antiproliferative action of EB1089 on breast cancer cells [2 1, 
35, 361. In vivo studies with rats have shown that EB 1089 has 
a decreased ability to affect calcium metabolism compared to 
1,25-(OH),D, [36]. Moreover, Colston and associates 
showed that EB1089 suppressed tumour growth in rats with 
chemically induced breast cancer [35]. Thus, EB1089 appears 
to be a promising analogue for the treatment of breast cancer. 
IGF-I and insulin are believed to play an important role in 
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the development and growth of breast tumours [l l-141. In 
oestrogen-responsive cells, insulin and the IGFs can contri- 
bute to oestrogen-induced growth [32-341. Thus, interrup- 
tion of insulin-IGF-induced growth by the vitamin D, com- 
pounds may affect both oestrogen-independent and 
oestrogen-dependent breast tumours. This may provide an 
explanation for the observation that vitamin D3 compounds 
inhibit the growth of breast cancer cells and tumours irrespec- 
tive of the presence of the oestrogen receptor [4, 371. 
Although most attention has focused on the tumour pro- 
moting role of the IGFs, insulin may also play a role in the 
growth and development of breast turnours, acting through its 
own receptor [ 121. The high doses of insulin needed for 
growth stimulation of MCF-7 cells (EC5,, = 1 &ml) suggests 
that insulin was acting through the type I IGF receptor, which 
has a low affinity for insulin, and mimicked the effect of IGF- 
I. However, the small inhibition of insulin-stimulated growth 
by oIR3 (24% inhibition) suggests that insulin acted predomi- 
nantly via the insulin receptor. In addition, the studies of 
Milazzo and colleagues [ 121 and Cullen and associates [14] 
with aIR3 suggested an involvement of the insulin receptor in 
the transmission of the mitogenic effect of insulin in breast 
cancer cells. The antibody was tested at a concentration lOO- 
fold higher than the KD of oIR3 for binding to the type I IGF 
receptor in MCF-7 cells [38]. In view of the high concen- 
trations of IGF-I needed to stimulate growth, this aIR3 con- 
centration could still be too low, which may explain its small 
effect on IGF-I-stimulated growth. 
The presence of specific insulin binding sites on MCF-7 
cells was demonstrated by binding studies with [1251]insulin. 
Half-maximal displacement of [iz51]insulin was achieved with 
insulin at 300 times lower concentrations than with IGF-I. 
Other reports have also demonstrated the presence of func- 
tional insulin receptors on several breast cancer cell lines, 
including MCF-7 [12]. In addition, a role of the insulin 
receptor in breast cancer initiation and/or progression is sup- 
ported by the observations that the insulin receptor expression 
is increased in human breast cancer specimens and that the 
insulin receptor content is positively correlated with tumour 
grade and size [39]. Lastly, an insulin analogue with enhanced 
mitogenic activity increased the incidence of mammary 
tumours in female rats [40]. 
Besides insulin, the IGF-I analogues, long R3 IGF-I and 
des(l-3)IGF-I, were also needed in high concentrations 
(0.5 &ml or more) to stimulate the growth of MCF-7 cells, 
whereas previous studies have shown that IGF-I and the IGF 
analogues can elicit a proliferative response at concentrations 
ranging from 1 to 50 r&ml [13, 14, 261. There are several 
possible explanations for the low sensitivity of the MCF-7 
cells to insulin and IGF-I, regardless of the receptor activation 
pathway. First, we used serum-free culture conditions, and 
possibly additional serum-derived factors play a synergistic 
role in the growth stimulation by insulin and IGF-I [32-341. 
Secondly, the cells could be less responsive because of the 
high basal growth rate. This could be due to the fact that 
MCF-7 cells produce autocrine acting growth factors [lo]. 
To gain insight into the mechanism of the antigrowth factor 
activity of 1,25-(OH),D, and EB1089, we studied several 
aspects of the insulin and IGF-I signal transduction pathway. 
First, it was shown that 1,25-(OH),D, and EB1089 did not 
suppress the insulin and IGF-I binding. The vitamin D3 
compounds had no direct effect on insulin and IGF-I binding 
after 48 h of treatment. At time points where the growth 
inhibition by the vitamin D, compounds was observed (8 
days), an increase of insulin and IGF-I binding was observed 
with treatment with 1,25-(OH),D, and EB1089. The physio- 
logical implications of these findings are not clear, but a 
similar inverse relation between receptor regulation and 
growth inhibition by 1,25-(OH),D, was observed for the 
epidermal growth factor receptor in BT-20 breast cancer 
cells [4 11. Possibly, the stimulation of the insulin and IGF-I 
binding is a secondary effect to 1,25-(OH),D, and EB1089 
treatment, which is not linked to the inhibitory effect on cell 
growth. A role of IGF-BPS in the growth inhibition by 1,25- 
(OH)*DS and EB 1089 is unlikely because of the use of insulin 
and analogues of IGF-I which reduced binding to IGF-BPS. 
We also studied two intracellular responses that can be 
activated by insulin and IGF-I: C-FOS mRNA expression [22, 
231 and MAP kinase activity [24]. The rapid induction of C- 
FOS mRNA expression by insulin was inhibited by 1,25- 
(OH),D,, indicating that C-FOS mRNA expression is a poss- 
ible target for 1,25-(OH),D, and analogues in the growth 
inhibition of these breast cancer cells. It should be noted that 
the inhibition of insulin-induced C-FOS mRNA expression 
could already be observed at lower concentrations than the 
inhibition of proliferation, indicating that inhibition of only C- 
FOS expression is not sufficient to inhibit insulin-induced cell 
growth. This is supported by the observation that the vitamin 
D, concentration which most potently inhibited the prolifer- 
ation had the weakest effect on C-FOS expression. Further- 
more, a stimulation of C-FOS mRNA levels by 1,25-(OH),D, 
was associated with inhibition of cell proliferation in the 
MCF-7 cell line [36] and in the HL-60 leukaemic cell line 
[42]. Finally, we studied whether MAP kinase is involved in 
growth inhibition by 1,25-(OH),D, and EB1089. MAP kinase 
has been detected in a wide variety of cells and tissues and is 
activated by a number of growth factors (insulin, IGF-I and 
epidermal growth factor), hormones and other extracellular 
signals. Activated MAP kinase in its turn phosphorylates other 
proteins, including the proto-oncogene products of myc and 
jun, which act as transcription factors [24]. However, it 
appeared that MAP kinase phosphorylation was not detected, 
which may imply that MAP kinase is not involved in the 
growth stimulation by insulin and IGF-I in the MCF-7 breast 
cancer cells. 
In conclusion, it was shown that 1,25-(OH),D, and the 
more potent analogue EB1089 block the mitogenic effect 
of insulin and IGF-I on MCF-7 breast cancer cells. It is 
questionable whether the observed growth inhibition of breast 
cancer cells by 1,25-(OH),D, and EB1089 is specific for 
insulin- and IGF-I-stimulated growth. Previously, we have 
shown that 1,25-(OH),D, also inhibits EGF-stimulated as 
well as oestradiol-stimulated growth [7, 2 I]. This led to the 
hypothesis that vitamin D3 compounds interfere with growth 
stimulatory agents at a late, common stage in the signal 
cascades leading stimulation of cell proliferation. The present 
observations that vitamin D, compounds also inhibit insulin- 
and IGF-I-stimulated growth supports this hypothesis. 
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